ISSN: 2167-0501
Anneliese Kohler*
Cancer treatment has seen remarkable progress in recent decades, largely due to advancements in targeted therapies, immunotherapies, and chemotherapeutic regimens. Despite these strides, drug resistance continues to be a formidable barrier to successful long-term cancer management. Both intrinsic and acquired resistance mechanisms compromise therapeutic efficacy, often resulting in tumor relapse or progression. At the heart of these resistance pathways lie intricate molecular changes ranging from genetic mutations to alterations in the tumor microenvironment that enable malignant cells to survive, adapt, and proliferate in the presence of therapeutic agents.
Published Date: 2025-03-04; Received Date: 2025-02-03